Veradermics, Incorporated (MANE) SEC Filings & Earnings Calls

Regulatory approval risk remains; FDA may require additional data or have safety concerns despite favorable profile.

“No treatment-related SAEs or cardiac AESIs, but FDA review is pending.”

Competition from existing treatments (e.g., topical minoxidil, finasteride) and potential new entrants.

“VDPHL01 is positioned as first FDA-approved oral pill in ~30 years, but market has established therapies.”

Insider/Institutional Selling

“SR One Fund II Aggregator and AMZL sold an aggregate of 321,749 shares ... at a price of $104.30 per share” · word for word

Insider/Institutional Selling

“SR One Fund II Aggregator and AMZL sold an aggregate of 321,749 shares ... at a price of $104.30 per share” · word for word

No approved products; reliance on VDPHL01 for future revenue.

“Veradermics’ limited operating history with no products approved for commercial sale; its success will depend on the approval and successful commercialization of VDPHL01.” · word for word

Increasing operating losses; R&D and G&A expenses rising significantly.

“R&D expenses increased from $14.3M to $18.6M; G&A expenses increased from $1.7M to $10.9M year-over-year.”

Clinical trial risk; Phase 3 data still pending.

“Topline data from Study '304' and 12-month data from Study '302' expected in 2H26; Study '306' topline data in 1H27.”

Pre-revenue clinical-stage company with no approved products

“We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale.” · word for word

Dependence on VDPHL01 success

“We currently anticipate that our success will depend on the approval and successful commercialization of VDPHL01, which is our lead product candidate.” · word for word

History of losses and need for additional financing

“We have incurred substantial losses since our inception, and we anticipate incurring substantial and increasing losses for the foreseeable future.” · word for word

No approved products; reliance on VDPHL01 for future revenue.

“Veradermics’ limited operating history with no products approved for commercial sale; its success will depend on the approval and successful commercialization of VDPHL01.” · word for word

Clinical trial risk; Phase 3 data still pending.

“Topline data from Study '304' and 12-month data from Study '302' expected in 2H26; Study '306' topline data in 1H27.”

Adverse events observed: hypertrichosis and peripheral edema.

“The most common adverse events were hypertrichosis and peripheral edema.” · word for word

Pre-revenue clinical-stage company with no approved products

“We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale.” · word for word

Dependence on VDPHL01 approval and commercialization

“We currently anticipate that our success will depend on the approval and successful commercialization of VDPHL01, which is our lead product candidate.” · word for word

Substantial additional capital needed

“We will require substantial additional financing to achieve our goals, and failure to obtain additional capital when needed, or on acceptable terms, would cause us to delay, limit, reduce or terminate our product development or commercialization efforts.” · word for word

Cash-pay market strategy may limit sales

“Our strategy of focusing on the cash-pay healthcare market for VDPHL01 may limit our ability to increase sales or achieve profitability.” · word for word

No approved products; reliance on VDPHL01 for future revenue.

“Veradermics’ limited operating history with no products approved for commercial sale; its success will depend on the approval and successful commercialization of VDPHL01.” · word for word

Increasing operating losses; R&D and G&A expenses rising significantly.

“R&D expenses increased from $11.4M to $20.9M; G&A expenses increased from $1.5M to $8.9M year-over-year; net loss widened from $12.4M to $27.2M.”

Clinical trial risk; Phase 3 data still pending.

“Topline data from Study '304' and 12-month data from Study '302' expected in 2H26; Study '306' enrollment ongoing.”

Dilution risk from issuance of 3,843,790 shares plus potential additional 576,568 shares via underwriter option.

“Public offering of 3,843,790 shares with option for additional 576,568 shares.” · word for word

Company has no approved products and requires substantial additional financing.

“Veradermics’ limited operating history with no products approved for commercial sale; need for substantial additional financing.” · word for word

Preliminary data subject to revision; no auditor review.

“This amount is preliminary and unaudited and is subject to completion of the Company’s financial closing procedures.” · word for word

Clinical trial failure risk; no approved products yet; cash runway depends on trial success

“Topline data expected in 2026; company is pre-revenue biopharmaceutical”

Clinical trial failure risk

“If we are unable to obtain regulatory approval for, and successfully commercialize, VDPHL01, or any of our other current or future product candidates, or experience significant delays in doing so, our business will be materially harmed.” · word for word

Capital need risk

“We will require substantial additional financing to achieve our goals, and failure to obtain additional capital when needed, or on acceptable terms, would cause us to delay, limit, reduce or terminate our product development or commercialization efforts.” · word for word

Competitive risk

“Our competitors may have significantly greater financial resources, established presence in the market and expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products than we do.” · word for word